Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity
Restricted accessResearch articleFirst published online February, 2016
Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity
This retrospective study aimed to compare the therapeutic response, including side effects, for oral baclofen versus oral tizanidine therapy with adjuvant botulinum toxin type A in a group of 64 pediatric patients diagnosed with static encephalopathy and spastic equinus foot deformity. Following botulinum toxin A treatment, clinical improvement led to the gradual reduction of baclofen or tizanidine dosing to one-third of the former dose. Gross Motor Functional Measure and Caregiver Health Questionnaire scores were markedly elevated post–botulinum toxin A treatment, with scores for the tizanidine (Gross Motor Functional Measure: 74.45 ± 3.72; Caregiver Health Questionnaire: 72.43 ± 4.29) group significantly higher than for the baclofen group (Gross Motor Functional Measure: 68.23 ± 2.66; Caregiver Health Questionnaire: 67.53 ± 2.67, P < .001). These findings suggest that the combined use of botulinum toxin A and a low dose of tizanidine in treating children with cerebral palsy appears to be more effective and has fewer side effects versus baclofen with adjuvant botulinum toxin A.
BaxMCFlodmarkOTydemanC. Definition and classification of cerebral palsy. From syndrome toward disease. Dev Med Child Neurol Suppl. 2007;109:39–41.
2.
OskouiMCoutinhoFDykemanJ. An update on the prevalence of cerebral palsy: a systematic review and meta-analysis. Dev Med Child Neurol. 2013;55:509–519.
3.
AisenMLKerkovichDMastJ. Cerebral palsy: clinical care and neurological rehabilitation. Lancet Neurol. 2011;10:844–852.
4.
MatthewsDJBalabanB. Management of spasticity in children with cerebral palsy. Acta Orthop Traumatol Turc. 2009;43:81–86.
5.
DelgadoMRHirtzDAisenM. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010;74:336–343.
6.
O’NeilMEFragalaMADumasHM. Physical therapy intervention for children with cerebral palsy who receive botulinum toxin A injections. Pediatr Phys Ther. 2003;15:204–215.
7.
SariogluBSerdarogluGTutuncuogluSOzerEA. The use of botulinum toxin type A treatment in children with spasticity. Pediatr Neurol. 2003;29:299–301.
8.
ElOPekerOKosayC. Botulinum toxin A injection for spasticity in diplegic-type cerebral palsy. J Child Neurol. 2006;21:1009–1012.
9.
WillisAWCrownerBBrunstromJE. High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy. Dev Med Child Neurol. 2007;49:818–822.
10.
HesseSBrandl-HesseBSeidelU. Lower limb muscle activity in ambulatory children with cerebral palsy before and after the treatment with Botulinum toxin A. Restor Neurol Neurosci. 2000;17:1–8.
11.
PapadonikolakisASVekrisMDKorompiliasAV. Botulinum A toxin for treatment of lower limb spasticity in cerebral palsy: gait analysis in 49 patients. Acta Orthop Scand. 2003;74:749–755.
12.
WeiglDMArbelNKatzK. Botulinum toxin for the treatment of spasticity in children: attainment of treatment goals. J Pediatr Orthop B. 2007;16:293–296.
13.
BerweckSHeinenF. Use of botulinum toxin in pediatric spasticity (cerebral palsy). Mov Disord. 2004;19: S162–S167.
14.
KomanLABrashearARosenfeldS. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics. 2001;108:1062–1071.
15.
GoldsteinEM. Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol. 2006;21:189–192.
16.
ChungCYChenCLWongAM. Pharmacotherapy of spasticity in children with cerebral palsy. J Formos Med Assoc. 2011;110:215–222.
ThomasCKHäger-RossCKKleinCS. Effects of baclofen on motor units paralysed by chronic cervical spinal cord injury. Brain. 2010;133:117–125.
19.
KitaMGoodkinDE. Drugs used to treat spasticity. Drugs. 2000;59:487–495.
20.
SaulinoMJacobsBW. The pharmacological management of spasticity. J Neurosci Nurs. 2006;38:456–459.
21.
WagstaffAJBrysonHM. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997;53:435–452.
22.
BrinILKurenkovALGotlibVI. The use of sirdalud in cerebral palsy in children. Zh Nevrol Psikhiatr Im S S Korsakova1999;99:30–33.
23.
Vásquez-BriceñoAArellano-SaldañaMELeón-HernándezSRMorales-OsorioMG. The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy. Rev Neurol. 2006;43:132–136.
24.
TiltonAVargus-AdamsJDelgadoMR. Pharmacologic treatment of spasticity in children. Semin Pediatr Neurol. 2010;17:261–267.
25.
PatelDRSoyodeO. Pharmacologic interventions for reducing spasticity in cerebral palsy. Indian J Pediatr. 2005;72:869–872.
26.
AlbrightAL. Baclofen in the treatment of cerebral palsy. J Child Neurol. 1996;11:77–83.
27.
DaiAI. Effectiveness of botulinum toxin type a in cerebral palsy: low dose or high dose?Neurol Psychiatry Brain Res. 2006;13:147–150.
28.
FlettPJ. Rehabilitation of spasticity and related problems in childhood cerebral palsy. J Paediatr Child Health. 2003;39:6–14.
ScholtesVADallmeijerAJKnolDL. The combined effect of lower-limb multilevel botulinum toxin type A and comprehensive rehabilitation on mobility in children with cerebral palsy: a randomized clinical trial. Arch Phys Med Rehabil. 2006;87:1551–1558.
31.
HsiehJTWolfeDLMillerWC. Spasticity outcome measures in spinal cord injury: psychometric properties and clinical utility. Spinal Cord. 2008;46:86–95.
32.
SchneiderJWGurucharriLMGutierrezALGaebler-SpiraDJ. Health-related quality of life and functional outcome measures for children with cerebral palsy. Dev Med Child Neurol. 2001;43:601–608.
33.
EdgarTS. Clinical utility of botulinum toxin in the treatment of cerebral palsy: comprehensive review. J Child Neurol. 2001;16:37–46.
34.
ArnonSSSchechterRInglesbyTV. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285:1059–1070.
35.
BakerRJasinskiMMaciag-TymeckaI. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol. 2002;44:666–675.
36.
WardAB. Spasticity treatment with botulinum toxins. J Neural Transm. 2008;115:607–616.
37.
DaiAIWasayMAwanS. Botulinum toxin type A with oral baclofen versus oral tizanidine: a nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity. J Child Neurol. 2008;23:1464–1466.
38.
CardosoESRodriguesBMBarrosoM. Botulinum toxin type A for the treatment of the spastic equinus foot in cerebral palsy. Pediatr Neurol. 2006;34:106–109.
